tradingkey.logo

Dianthus Therapeutics surges again ahead of planned equity raise

ReutersSep 9, 2025 5:17 PM

Dianthus Therapeutics' DNTH.O shares surge 13.2% on Tues to $36, highest since Apr 2022, adding to strong gain in previous session

DNTH shares on Mon finished up 20% after co's mid-stage trial win for its muscle-weakening drug claseprubart

After the bell Mon, co commenced $150 mln stock offering to fund preclinical and clinical development activities, and for working capital and general purposes

Jefferies, TD Cowen, Evercore and Stifel are joint bookrunners for the offering

Dianthus has ~32.19 mln shares outstanding for about $1.2 bln current market cap

Raymond James early Tues hiked its PT by $7 to $63

All 13 brokerages covering DNTH are bullish with "strongbuy" avg rating; median PT is $51.50, per LSEG data

With the move on the session, shares up ~90% over the past three months, putting them up ~65% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI